The four-peptide stack
Inside the KLOW Stack: The Four Peptides
KPV, GHK-Cu, BPC-157 and TB-500 — four distinct molecules, four separate research records, one co-formulated vial. Here is what each current is, what it does, and what the KLOW stack cannot yet claim as a whole.
In plain words
The KLOW stack is four separate compounds dissolved together in one vial — not one molecule, not a fusion. Each has its own chemical identity, its own research record, and its own mechanism. This page walks each of the four components: what it is structurally, what the published research says it does, and the honest boundary between what its own studies show and what the blend as a whole has never been tested for. The combination has no controlled data. Every 'synergy' claim is a mechanistic extrapolation, and a pharmacokinetic mismatch (the tripeptides KPV and GHK-Cu clear far faster than BPC-157) is inherent in the design.
KPV — the anti-inflammatory current
Structure: Linear tripeptide L-Lys-L-Pro-L-Val, the C-terminal residues 11-13 of alpha-MSH (alpha-melanocyte-stimulating hormone, the 13-residue parent hormone). Sequence: Lys-Pro-Val. MW: 342.44 Da. CAS: 67727-97-3. Typical vial share: 10 mg (12.5% of the canonical 80 mg vial).
Mechanism: KPV's defining mechanistic feature is substrate recognition by PepT1 (SLC15A1, the di/tripeptide transporter that pulls small peptides into cells lining inflamed gut and immune tissue). Km ~160 μM. Inside the cell, KPV inhibits NF-kB p65/RelA nuclear import and MAPK (ERK/p38) signaling, reducing TNF-alpha, IL-6, IL-1beta and IL-8 output.
Research record: In human intestinal epithelial lines (Caco2-BBE, HT29-Cl.19A) and Jurkat T cells, 10 nM KPV reduced NF-kB activation and pro-inflammatory cytokine secretion. Oral KPV at 100 μM reduced severity of DSS- and TNBS-induced colitis in mice [3]. The (CKPV)₂ dimer extended the KPV motif to anti-fungal / macrophage M2 polarization in a Candida vaginitis mouse model [13]. Oral colon-targeted nanoparticle delivery of KPV reduced colitis in mice, establishing the delivery-platform lineage [14].
Honest boundary: No approved KPV monotherapy exists. Human data are limited to delivery pilots and the IBD program. The anti-inflammatory effects documented in cells and mice have not been confirmed in a human clinical trial.
GHK-Cu — the matrix and skin current
Structure: Tripeptide Gly-His-Lys chelated 1:1 to a Cu(II) ion. MW: 402.92 Da. CAS: 89030-95-5. Typical vial share: 50 mg (~62.5% of the canonical 80 mg vial, the mass-dominant component). First isolated from human plasma by Loren Pickart in 1973; endogenous plasma levels decline ~60% from age 20 to 60 [4].
Mechanism: GHK-Cu is a broad transcriptomic modulator — at low-nanomolar concentrations in human fibroblasts, it shifts expression of approximately 31.2% of assayed protein-coding genes ≥50% toward tissue-repair, antioxidant defense, DNA repair and protein-quality-control programs [5]. It stimulates procollagen-I and procollagen-IV, dermatan sulfate, chondroitin sulfate, decorin and elastin synthesis, and delivers copper for lysyl oxidase (the copper-dependent enzyme that crosslinks newly synthesized collagen fibers into load-bearing structure). Suppresses TGF-beta-1, TNF-alpha and protein glycation.
Research record: Collagen synthesis stimulated at 10⁻¹²–10⁻⁹ M in human fibroblast cultures, no change in cell number [8]. Multi-modal matrix stimulation (collagen, elastin, VEGF, FGF-2, NGF, erythropoietin; suppressed TGF-beta-1, TNF-alpha) reviewed across human and animal models [9]. Topical copper permeated ex-vivo human dermatomed skin at 2.43 ± 0.51 × 10⁻⁴ cm/h; 97 ± 6.6 μg/cm² retained as dermal depot over 48 h [10]. Hair count: +52.6 / +71.5 vs +9.6 for placebo (p<0.05) in a 6-month trial of 45 men with androgenetic alopecia [11]. Melanin synthesis link via copper-dependent pathway [15].
Honest boundary: The robust data are topical and in vitro. Systemic GHK-Cu has no approved indication. The transcriptomic breadth is a signal that needs cautious interpretation — scope of gene regulation is not a confirmed outcome list.
BPC-157 — the angiogenic current
Structure: Synthetic 15-amino-acid peptide Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. MW: 1419.53 Da. CAS: 137525-51-0. Typical vial share: 10 mg (12.5% of the canonical 80 mg vial). Originally developed as PL 14736 for inflammatory bowel disease; derived from a partial sequence of a protein identified in human gastric juice.
Mechanism: Activates the VEGFR2 (vascular endothelial growth factor receptor 2)/PI3K/Akt/eNOS angiogenic axis — the cellular pathway for building new blood vessels from existing ones. Upregulates the growth-hormone receptor in tendon fibroblasts. Modulates the nitric-oxide system partly resistant to L-NAME, suggesting an NO-related mechanism distinct from classical NOS. FDA placed BPC-157 in category 2 of the 503A bulk-substance review.
Research record: Fully transected rat Achilles tendon healing across biomechanical, functional, microscopic and macroscopic measures at 10 μg, 10 ng and 10 pg/rat IP once daily; in-vitro tendocyte outgrowth stimulation [2]. A 2025 first-in-human IV safety pilot of 10 mg day 1 / 20 mg day 2 in two healthy adults found no adverse events and no measurable biomarker changes [6]. A 2026 Sports Medicine review confirmed favorable animal-model data for musculoskeletal repair but flagged scarce human safety data and regulatory absence [7].
Honest boundary: Human data are a 2-person safety pilot and small case series. No efficacy trial in humans. The rodent literature is large; cross-species translation is unconfirmed.
TB-500 — the cell-migration current
Structure: Synthetic N-acetylated heptapeptide Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, the LKKTET actin-binding motif of the 43-amino-acid native protein thymosin beta-4 (Tbeta4). MW: 889.02 Da. Typical vial share: 10 mg (12.5% of the canonical 80 mg vial).
Critical distinction: Most foundational efficacy data in the literature are for full-length native thymosin beta-4, NOT the short TB-500 fragment. The fragment sequesters G-actin (globular monomeric actin — the raw building material cells use to polymerize a new leading edge and migrate forward), a step mechanistically linked to cell migration and re-epithelialization. Full-length Tbeta4 also activates integrin-linked kinase (ILK) and mobilizes epicardial progenitor cells — activities established for the native protein, not confirmed for the fragment.
Research record: Full-length thymosin beta-4: +42% re-epithelialization at 4 days, +61% at 7 days versus saline in rat full-thickness wounds; wound contraction ≥11% by day 7; collagen deposition and angiogenesis raised; 10 pg stimulated keratinocyte migration 2-3-fold [1]. Clinical-grade 0.1% RGN-259 ophthalmic solution (Tbeta4) promoted corneal healing in human studies [12]. A 2026 Sports Medicine review includes TB-500/thymosin beta-4 among unapproved peptides with favorable animal data and scarce human safety evidence [7].
Regulatory note: Thymosin beta-4 / TB-500 is on the WADA Prohibited List (S2, peptide hormones and growth factors), banned at all times in and out of competition. Using KLOW implicates anti-doping rules in athletic-research contexts regardless of intent.
Honest boundary: The TB-500 fragment is not the native protein. Efficacy data derived from Tbeta4 does not automatically transfer to the short synthetic fragment, and no study has confirmed it does.